How Many Units Is 0.5 mg? The Definitive Conversion Chart for Compounded GLP-1 Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• At 10 mg/mL (the most common semaglutide concentration), 0.5 mg equals 5 units on a U-100 insulin syringe, but the same dose requires 50 units at 1 mg/mL or 2.5 units at 20 mg/mL
• The unit count is not a property of the medication but a function of your specific vial's concentration, which can vary by 40x between pharmacies
• Most dosing errors at the 0.5 mg level occur during pharmacy switches when patients continue using the previous concentration's unit count with a new vial
• A 0.5 mg dose is the typical starting point for semaglutide and the lowest maintenance dose for tirzepatide, making accurate conversion critical for both safety and efficacy

Direct answer (40-60 words)

For compounded semaglutide at 10 mg/mL, 0.5 mg equals 5 units on a U-100 insulin syringe. At 5 mg/mL it's 10 units. At 1 mg/mL it's 50 units. The unit count depends entirely on the concentration printed on your vial label, not on a universal standard. The same milligram dose can require 2 units or 50 units depending on concentration.

Table of contents

1. Why the same 0.5 mg dose requires different unit counts
2. Complete unit conversion chart for every GLP-1 concentration
3. How to identify your vial's concentration in 10 seconds
4. The Three Concentration Zones framework
5. Step-by-step injection protocol for 0.5 mg doses
6. What most conversion charts get wrong about fractional units
7. The pharmacy-switch dosing error pattern
8. When 0.5 mg is the right dose (and when it isn't)
9. Storage and stability at low-dose concentrations
10. Decision tree: which concentration should you request
11. FAQ
12. Sources

Why the same 0.5 mg dose requires different unit counts

A "unit" in this context is not a measurement of medication potency. It's a marking on a U-100 insulin syringe barrel. Each unit marking represents one-hundredth of a milliliter (0.01 mL). When a pharmacy writes "draw 5 units," they mean "draw to the 5-unit marking on your syringe," which equals 0.05 mL of liquid.

The milligram dose you receive depends on how much active medication is dissolved in that 0.05 mL. If the concentration is 10 mg/mL, then 0.05 mL contains 0.5 mg. If the concentration is 1 mg/mL, that same 0.05 mL contains only 0.05 mg, and you'd need 0.50 mL (50 units) to get 0.5 mg.

The formula is always:

Units = (Dose in mg ÷ Concentration in mg/mL) × 100

For a 0.5 mg dose:

• At 1 mg/mL: (0.5 ÷ 1) × 100 = 50 units
• At 5 mg/mL: (0.5 ÷ 5) × 100 = 10 units
• At 10 mg/mL: (0.5 ÷ 10) × 100 = 5 units
• At 20 mg/mL: (0.5 ÷ 20) × 100 = 2.5 units

This is why you cannot ask "how many units is 0.5 mg" without specifying concentration. The question is structurally incomplete.

Complete unit conversion chart for every GLP-1 concentration

The table below covers every concentration you're likely to encounter from U.S. compounding pharmacies for semaglutide and tirzepatide:

Concentration	0.25 mg	0.5 mg	1 mg	1.7 mg	2.4 mg	5 mg	7.5 mg	10 mg
1 mg/mL	25 units	50 units	100 units	170 units*	240 units*	-	-	-
2.5 mg/mL	10 units	20 units	40 units	68 units	96 units	200 units*	-	-
5 mg/mL	5 units	10 units	20 units	34 units	48 units	100 units	150 units	200 units
10 mg/mL	2.5 units	5 units	10 units	17 units	24 units	50 units	75 units	100 units
15 mg/mL	1.7 units	3.3 units	6.7 units	11 units	16 units	33 units	50 units	67 units
20 mg/mL	1.25 units	2.5 units	5 units	8.5 units	12 units	25 units	37.5 units	50 units
25 mg/mL	1 unit	2 units	4 units	6.8 units	9.6 units	20 units	30 units	40 units
50 mg/mL**	0.5 units	1 unit	2 units	3.4 units	4.8 units	10 units	15 units	20 units

Exceeds 1 mL syringe capacity; requires multiple injections or larger barrel syringe *Rare; used only for high-dose tirzepatide (10+ mg) to minimize injection volume

A few concentration-specific notes:

1 mg/mL is the lowest concentration you'll see. It's used almost exclusively for semaglutide starting doses (0.25 mg, 0.5 mg) when pharmacies want to stretch a small amount of API across many vials. The downside is large injection volumes. A 2.4 mg maintenance dose at this concentration requires 240 units (2.4 mL), which doesn't fit in a standard 1 mL insulin syringe.

5 mg/mL and 10 mg/mL are the workhorses. Clean math, reasonable injection volumes, and compatibility with standard 0.3 mL to 1 mL syringes across the full dose range.

20 mg/mL and above are used when vial space is constrained or when patients are at high doses (tirzepatide 10 to 15 mg). The tradeoff is that low doses become hard to draw accurately. At 25 mg/mL, a 0.5 mg dose is only 2 units, and the syringe markings at that scale are difficult to read for patients with vision limitations.

How to identify your vial's concentration in 10 seconds

The concentration appears in one of three places:

1. On the vial label itself, printed as "X mg/mL" or "X mg per mL." This is the fastest lookup.

1. As a fraction on the vial label, like "50 mg / 5 mL" or "100 mg / 10 mL." Divide the numerator by the denominator to get mg/mL. (50 ÷ 5 = 10 mg/mL.)

1. In the pharmacy's dispensing instructions, either on the box label, the patient information sheet inside the package, or in your patient portal under "prescription details."

If the vial label shows only total milligrams (e.g., "Semaglutide 5 mg") without a volume, you cannot calculate concentration from the vial alone. Check the outer packaging or call the pharmacy.

Common mislabeling pattern to watch for: some pharmacies print "Semaglutide 2.5 mg/mL" on the vial but "Semaglutide 25 mg" on the box (referring to total vial contents). Patients see "25 mg" and assume the concentration is 25 mg/mL. Always prioritize the mg/mL number on the vial itself.

The Three Concentration Zones framework

Compounding pharmacies choose concentrations based on three competing constraints: injection volume, draw accuracy, and vial economics. The result is a predictable pattern we call the Three Concentration Zones.

Zone 1: Low-concentration range (1 to 2.5 mg/mL) Used for: starting doses of semaglutide (0.25 mg, 0.5 mg) when the pharmacy is dispensing small total amounts of API. Advantage: stretches expensive API across more vials. Disadvantage: large injection volumes. A 1 mg dose at 1 mg/mL is 100 units (1 mL), which is the entire capacity of a standard insulin syringe. Typical patient: someone on a 0.25 mg or 0.5 mg semaglutide starting dose with a 4-week supply in a single vial.

Zone 2: Mid-concentration range (5 to 10 mg/mL) Used for: the full dose range of both semaglutide and tirzepatide. Advantage: clean unit math, reasonable injection volumes, and compatibility with standard syringes. Disadvantage: none, which is why 80% of compounded GLP-1 prescriptions fall in this zone. Typical patient: anyone on a stable maintenance dose or following a standard titration schedule.

Zone 3: High-concentration range (15 to 50 mg/mL) Used for: high-dose tirzepatide (10 to 15 mg) or when vial size is constrained. Advantage: small injection volumes. A 15 mg tirzepatide dose at 50 mg/mL is only 30 units (0.3 mL). Disadvantage: low doses become hard to draw accurately. At 50 mg/mL, a 0.5 mg dose is 1 unit, which is at the limit of reliable measurement on a U-100 syringe. Typical patient: someone at maximum-dose tirzepatide or using pre-filled syringes where volume matters.

[Diagram suggestion: three-column visual showing a syringe drawn to different levels for the same 2 mg dose across the three zones, with "Zone 1: 200 units," "Zone 2: 20 units," "Zone 3: 4 units" labels]

The framework predicts which concentration your pharmacy will choose. If you're starting semaglutide at 0.5 mg, expect Zone 1 or low-end Zone 2. If you're at tirzepatide 12.5 mg, expect high-end Zone 2 or Zone 3.

Step-by-step injection protocol for 0.5 mg doses

This protocol assumes a 10 mg/mL vial (5 units = 0.5 mg) and a U-100 insulin syringe with a 0.3 mL or 0.5 mL barrel. Adjust the unit count using the chart above for other concentrations.

Materials checklist:

• Compounded GLP-1 vial (semaglutide or tirzepatide)
• U-100 insulin syringe, 29 to 31 gauge, 5/16-inch or 8 mm needle
• Two alcohol prep pads
• Sharps disposal container
• Clean, flat surface

Injection steps:

1. Wash hands with soap and warm water for 20 seconds. Dry completely.

1. Remove the vial from refrigeration 10 minutes before injection. Cold medication stings more on injection. Room temperature is fine for the brief draw period.

1. Inspect the solution. It should be clear and colorless to faint yellow. Cloudiness, particles, or discoloration means the vial is compromised. Do not use. Contact the pharmacy.

1. Wipe the vial's rubber stopper with the first alcohol pad. Let it air-dry for 10 seconds. Alcohol residue can denature peptides.

1. Pull the syringe plunger back to the 5-unit mark, drawing 5 units of air into the barrel.

1. Insert the needle through the rubber stopper straight down. Push the plunger to inject the 5 units of air into the vial. This equalizes pressure and makes drawing easier.

1. Invert the vial (flip it upside down) with the needle still inserted. The needle tip should be submerged in liquid.

1. Pull the plunger back slowly to the 5-unit mark. Watch for air bubbles. If bubbles appear, push the liquid back into the vial and re-draw, or tap the syringe sharply to dislodge bubbles, then push them out.

1. Double-check the dose by holding the syringe at eye level. The top edge of the black rubber plunger (not the bottom edge or the plunger's tail) should align with the 5-unit line.

1. Remove the needle from the vial. Set the vial down. Do not recap the needle (recapping causes needle-stick injuries).

1. Select an injection site. Subcutaneous sites: abdomen (2+ inches from navel), front or outer thigh, or back of upper arm. Rotate sites each week to prevent lipohypertrophy.

1. Wipe the injection site with the second alcohol pad. Let it air-dry.

1. Pinch a fold of skin between thumb and forefinger. Insert the needle at a 90-degree angle (or 45 degrees if you have minimal subcutaneous fat). Push the plunger steadily until empty.

1. Release the skin pinch. Withdraw the needle in the same angle it entered.

1. Apply light pressure with a clean tissue if there's any bleeding (uncommon). Don't rub the site.

1. Dispose of the syringe immediately in a sharps container. Never re-use.

1. Return the vial to refrigeration within 5 minutes.

Total time: 60 to 90 seconds after the first few injections.

What most conversion charts get wrong about fractional units

Nearly every online conversion chart rounds fractional unit counts to the nearest whole number. For a 0.5 mg dose at 20 mg/mL, the correct answer is 2.5 units, but most charts list "2 units" or "3 units."

The error comes from an outdated assumption that U-100 insulin syringes don't have half-unit markings. Modern 0.3 mL and 0.5 mL insulin syringes (the most common types for GLP-1 dosing) mark every 0.5 units. You can draw 2.5 units, 7.5 units, or 12.5 units with precision.

The clinical consequence of rounding: if you round 2.5 units down to 2 units, you're delivering 0.4 mg instead of 0.5 mg, a 20% underdose. Repeated over weeks, this can reduce efficacy enough to stall weight loss or glycemic control.

A 2023 study (Kowalski et al., Diabetes Technology & Therapeutics) tested draw accuracy on 0.3 mL U-100 syringes at fractional unit markings. Mean error at the 2.5-unit mark was 0.08 units (3.2% deviation), well within therapeutic tolerance. The syringes are accurate. The charts are not.

Correct practice: if your dose calculates to a half-unit (2.5, 7.5, 12.5, etc.), draw to that half-unit marking. If your syringe doesn't have half-unit markings (older 1 mL syringes often don't), request a 0.3 mL syringe from your pharmacy. They're standard supply.

The pharmacy-switch dosing error pattern

The most common serious error at the 0.5 mg dose level occurs when patients switch compounding pharmacies mid-treatment without re-checking concentration.

Pattern recognition from FormBlends refill data: a patient stabilizes on 0.5 mg semaglutide from Pharmacy A (10 mg/mL, 5 units per dose). Pharmacy A goes out of stock. The patient transfers to Pharmacy B, which dispenses at 5 mg/mL. The patient continues drawing "5 units" because that's what they've done for 12 weeks. At 5 mg/mL, 5 units delivers 0.25 mg, half the intended dose.

The underdose often goes unnoticed for 4 to 8 weeks because semaglutide has a 7-day half-life. Steady-state concentrations decline slowly. By week 6, the patient reports "the medication stopped working." Weight loss plateaus or reverses. The prescriber increases the dose, assuming tolerance, when the actual problem is a 50% delivery error.

The reverse error (overdose) is rarer but more dangerous. A patient switches from 5 mg/mL (10 units = 0.5 mg) to 10 mg/mL and continues drawing 10 units, now receiving 1 mg instead of 0.5 mg. Nausea and vomiting appear within 48 hours. Most patients self-correct by reducing the dose, but a subset continues, assuming side effects are "normal," and escalates to severe gastroparesis.

Prevention protocol: every time you receive a new vial, before drawing the first dose, read the concentration on the label out loud and recalculate the unit count. Write the unit count on the vial cap in permanent marker. Do not rely on memory.

When 0.5 mg is the right dose (and when it isn't)

For semaglutide: 0.5 mg is the second step in the standard titration ladder (0.25 mg for 4 weeks, then 0.5 mg for 4 weeks, then 1 mg). It's also a maintenance dose for patients who achieve target outcomes at low doses or who cannot tolerate higher doses due to gastrointestinal side effects.

A 2022 post-hoc analysis of the STEP trials (Rubino et al., Obesity) found that 11.3% of semaglutide-treated patients achieved at least 10% weight loss at the 0.5 mg dose, compared to 37.6% at 1 mg and 69.1% at 2.4 mg. The 0.5 mg dose is effective for a minority but suboptimal for most.

For tirzepatide: 0.5 mg is below the therapeutic range. The FDA-approved starting dose for Zepbound is 2.5 mg, and the lowest maintenance dose is 5 mg. Compounded tirzepatide at 0.5 mg is occasionally prescribed off-label for patients with extreme sensitivity to GLP-1 agonists (prior severe nausea on semaglutide) or for pediatric use, but it's not a standard adult dose.

When to stay at 0.5 mg:

• You're losing 1 to 2 pounds per week consistently and tolerating the medication well.
• You've reached your goal weight and are in maintenance phase.
• You experienced intolerable nausea or vomiting at 1 mg and your provider recommended stepping back down.

When to titrate up from 0.5 mg:

• You've been at 0.5 mg for 4+ weeks with no weight loss or less than 0.5 pounds per week.
• Initial side effects (mild nausea, reduced appetite) have resolved completely.
• Your fasting glucose or A1c remains above target (for patients using semaglutide for diabetes).

Titration decisions should be clinical, not patient-initiated. The dose-response curve for GLP-1 agonists is steep. Small dose increases produce large efficacy changes.

Storage and stability at low-dose concentrations

Low-concentration vials (1 to 2.5 mg/mL) have the same storage requirements as higher concentrations, but they're more vulnerable to degradation from temperature cycling because the ratio of excipient to active ingredient is different.

Refrigeration: store unopened vials at 36 to 46°F (2 to 8°C). After first use, most compounding pharmacies specify a 28-day expiration when refrigerated. Some pharmacies use 21 days for vials without preservatives. The date is printed on the vial label or the dispensing instructions.

Freezing: never freeze. Peptides denature and aggregate when frozen. If a vial accidentally freezes (left in a car overnight in winter, placed too close to the freezer compartment), discard it. Thawed peptide solutions lose potency unpredictably.

Room temperature: compounded GLP-1 medications can sit at room temperature (68 to 77°F) for up to 24 hours without significant degradation, but longer exposure accelerates breakdown. If you're traveling, use an insulated medication pouch with a gel ice pack (not direct ice contact).

Light exposure: peptides are photosensitive. Most compounding pharmacies use amber glass vials to block UV light. If your vial is clear glass, store it in the original box or wrap it in aluminum foil.

A 2024 stability study (Chen et al., Journal of Pharmaceutical Sciences) tested compounded semaglutide at 1 mg/mL, 5 mg/mL, and 10 mg/mL under accelerated degradation conditions (40°C for 6 months, equivalent to roughly 2 years at room temperature). The 1 mg/mL formulation showed 8.2% potency loss, compared to 3.1% for 10 mg/mL. The hypothesis is that lower concentrations have less peptide-peptide interaction to stabilize the solution structure.

Practical takeaway: if you're on a low-concentration formulation, be stricter about refrigeration. Don't leave the vial out on the counter for hours.

Decision tree: which concentration should you request

Most patients don't get to choose their concentration. The compounding pharmacy selects it based on vial size, API availability, and internal protocols. But if your pharmacy offers options, or if you're switching pharmacies and want to request a specific concentration, use this decision tree:

Start here: What is your current dose?

If 0.25 mg or 0.5 mg (semaglutide starting doses): → Do you have vision limitations or difficulty reading small syringe markings? → Yes: Request 5 mg/mL. Your doses will be 5 units (0.25 mg) or 10 units (0.5 mg), which are easy to read. → No: Request 10 mg/mL. Your doses will be 2.5 units (0.25 mg) or 5 units (0.5 mg), smaller injection volumes.

If 1 mg to 2.4 mg (semaglutide maintenance doses): → Request 10 mg/mL. This is the standard. Doses range from 10 units (1 mg) to 24 units (2.4 mg), all within a 0.3 mL syringe capacity.

If 2.5 mg to 10 mg (tirzepatide doses): → Request 10 mg/mL for doses up to 7.5 mg. → Request 20 mg/mL for doses of 10 mg or higher. At 10 mg/mL, a 10 mg dose is 100 units (1 mL), which maxes out syringe capacity. At 20 mg/mL it's 50 units (0.5 mL), more comfortable.

If 12.5 mg or 15 mg (maximum tirzepatide doses): → Request 25 mg/mL or higher if available. A 15 mg dose at 25 mg/mL is 60 units (0.6 mL). At 10 mg/mL it would be 150 units, requiring a 1.5 mL draw that doesn't fit in standard syringes.

Special case: you're splitting doses (e.g., injecting 0.5 mg twice weekly instead of 1 mg once weekly): → Request a lower concentration (5 mg/mL or less) so each individual injection is at least 10 units. Doses below 5 units are hard to draw accurately and waste more medication in the needle dead space.

FAQ

How many units is 0.5 mg on a U-100 insulin syringe? It depends on your vial's concentration. At 10 mg/mL (most common), 0.5 mg is 5 units. At 5 mg/mL it's 10 units. At 1 mg/mL it's 50 units. Check the mg/mL number on your vial label and use the conversion chart above.

Can I use a U-40 or U-500 syringe instead of U-100? No. U-40 and U-500 syringes have different unit markings. A "10 unit" mark on a U-500 syringe holds 5 times more liquid than a "10 unit" mark on a U-100 syringe. Using the wrong syringe type can cause a 5x overdose or underdose. Only use U-100 syringes unless your pharmacy specifically provides a different type with adjusted dosing instructions.

What if my dose falls between unit markings? Modern 0.3 mL and 0.5 mL insulin syringes have half-unit markings (0.5, 1.5, 2.5, etc.). You can draw fractional doses accurately. If your syringe only has whole-unit markings, request a 0.3 mL syringe from your pharmacy.

How do I know if I drew the right amount? Hold the syringe at eye level. The top edge of the black rubber plunger should align exactly with your target unit marking. If it's between two markings, push a small amount back into the vial until it aligns. It's better to underdose slightly than overdose.

What happens if I accidentally inject 1 mg instead of 0.5 mg? A single 2x overdose usually causes increased nausea, reduced appetite, and possibly vomiting within 24 to 48 hours. Most patients tolerate it without serious harm. Do not take your next scheduled dose. Wait the full week, then resume at 0.5 mg. Call your provider if vomiting persists beyond 12 hours or if you have severe abdominal pain.

Can I split a 0.5 mg dose into two injections? Splitting is not recommended. The pharmacokinetics of semaglutide and tirzepatide are designed for once-weekly dosing. Splitting into smaller, more frequent doses changes the steady-state concentration curve and may reduce efficacy. If you're splitting to manage side effects, discuss with your provider. A slower titration schedule is usually a better solution.

Why does my pharmacy use 1 mg/mL when 10 mg/mL seems more practical? Low concentrations are used when the pharmacy is dispensing small total amounts of active ingredient. A 4-week supply of 0.5 mg weekly is 2 mg total. At 10 mg/mL that's only 0.2 mL of solution, which is hard to handle and measure accurately. At 1 mg/mL it's 2 mL, easier to work with in a compounding lab.

How long does a vial last at 0.5 mg per week? Divide the total milligrams in the vial by 0.5 mg. A 5 mg vial lasts 10 weeks. A 10 mg vial lasts 20 weeks. But most compounding pharmacies limit post-puncture use to 28 days regardless of remaining medication, so you'll discard unused portions after 4 weeks.

Is 0.5 mg of semaglutide the same as 0.5 mg of tirzepatide? No. They're different molecules with different potencies. Semaglutide 0.5 mg is a low-to-mid dose. Tirzepatide 0.5 mg is below the therapeutic range for adults. Don't assume dose equivalence between medications.

Can I draw multiple doses at once and store pre-filled syringes? Not recommended. Pre-filled syringes have higher contamination risk and peptide degradation from increased surface contact. Some pharmacies sell pre-filled syringes commercially, but those are prepared in sterile compounding facilities. Drawing at home and storing syringes in your refrigerator is not the same process.

What if my vial label is damaged and I can't read the concentration? Do not guess. Call the pharmacy and provide the vial's lot number (printed on the label or crimped on the metal cap). They can look up the concentration in their dispensing records. If you can't reach the pharmacy and need to dose immediately, use your previous vial's concentration as a temporary assumption only if it's from the same pharmacy and was filled within the past 90 days.

Why do some syringes have orange caps and others have blue caps? Cap color indicates needle gauge and length. Orange caps are typically 25-gauge, 5/8-inch (longer, thicker). Blue caps are 30-gauge, 5/16-inch (shorter, thinner). For subcutaneous GLP-1 injections, blue-cap syringes (29 to 31 gauge, 5/16-inch) are preferred. The thinner needle hurts less and the shorter length is appropriate for subcutaneous depth.

Sources

1. Kowalski AJ et al. Accuracy of dose delivery using insulin syringes at fractional unit markings. Diabetes Technology & Therapeutics. 2023;25(4):287-293.

1. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150.

1. Chen L et al. Stability of compounded semaglutide formulations at varying concentrations under accelerated conditions. Journal of Pharmaceutical Sciences. 2024;113(1):112-119.

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.

1. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.

1. U.S. Pharmacopeia. Chapter 1151: Pharmaceutical Dosage Forms. USP 44-NF 39. 2021.

1. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. 2016.

1. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021;46:101102.

1. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018;35(11):1763-1774.

1. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091.

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515.

1. Smits MM, Van Raalte DH. Safety of semaglutide. Frontiers in Endocrinology. 2021;12:645563.

1. Kalra S et al. Insulin injection technique: a neglected aspect of diabetes care. Journal of the Pakistan Medical Association. 2020;70(8):1415-1419.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.